“Lung Cancer Talk”: A Review of Data from the ASCO 2020 Virtual Meeting - Episode 1

RET Fusion+ mNSCLC

, , ,
Now Viewing
EP. 1: RET Fusion+ mNSCLC
EP. 2: MET Exon 14 Mutations in mNSCLC
EP. 3: HER2 Targeted Therapy for Treatment of NSCLC
EP. 4: KRAS-Mutant NSCLC
EP. 5: EGFR Exon 20 Mutations in NSCLC
EP. 6: Updates on I/O Therapy for Non-Driver mNSCLC

Updated data in RET fusion+ metastatic non–ؘsmall-cell lung cancer and insights on approaching testing for RET fusions.

Data from the following clinical trials are discussed:

  • Selpercatinib (LOXO-292) in patients with RET-fusion+ non–small cell lung cancer. (Goto K et al. 2020 ASCO annual meeting. Abstract 3584.)

  • Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non–small cell lung cancer patients on the LIBRETTO-001 trial. (Subbiah V et al. 2020 ASCO annual meeting. Abstract 9516.)

  • Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients with advanced RET fusion+ non–small cell lung cancer. (Gainor JF et al. 2020 ASCO annual meeting. Abstract 9515.)